Most Recent
The NSW Government is mulling cross-claims against construction firms ALTRAC and Acciona in a class action alleging the government failed to minimise disruptions from the Sydney light rail project.
And then there were four. Plaintiffs law firm Slater & Gordon wants to consolidate its AMP shareholder class action with Maurice Blackburn's case and hand over the reins to its rival, a deal signed the day the Full Federal Court affirmed the power of judges to shut down competing class actions.
Hastie Group's liquidators have offered to drop their $124 million case against two dozen major builders if the companies agree to pay an undisclosed sum toward their unpaid bills, a court heard Friday.
The showdown between five law firms vying to lead a class action over the AMP fees for no service scandal kicked off in the NSW Supreme Court Thursday with counsel for one case saying the contest, although costly and consuming, would ultimately be a win for all class action participants.
Former HWL Ebsworth special counsel Dr Gary Rumble's insistence that he believed he had carte blanche to criticise one of the law firm's clients is an "untenable stretch," the Federal Court heard Wednesday.
Medical device maker B. Braun Melsungen is appealing a ruling that invalidated its intravenous catheter patents and dismissed allegations of infringement against rival Becton Dickinson.
A judge applied the "wrong test" when he considered the reputation of a trade mark in an infringement case alleging the marks of rival meat processors were deceptively similar, a Full Federal Court has found.
Pharmaceutical giant Wyeth has accused Merck Sharp & Dohme of a "baseless" patent invalidity case, saying on the second day of trial over the world's best selling vaccine that the development of its patented Prevnar 13 pneumococcal shot was anything but obvious, as its rival contends.
The Commonwealth Bank of Australia is open to a proposal to consolidate two shareholder class actions filed over alleged breaches of anti-money laundering and counter-terrorism laws, but will address any "devil in the details", a lawyer for the bank told a court Tuesday.
A showdown between global pharmaceutical giants over the world's best selling vaccine began Monday in Federal Court, with Merck Sharp & Dohme claiming three patents for Prevnar 13 sold by Pfizer's Wyeth are invalid and that its own vaccine offers greater protection against pneumococcal bacteria.